Cardiff Lexington Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue declined year-over-year due to fewer surgical procedures, but positive adjusted EBITDA was achieved. Working capital constraints and higher interest expenses impacted profitability, while expansion and M&A remain central to the growth strategy.
Fiscal Year 2025
-
Revenue grew 40% year-over-year to $11.5 million, driven by higher patient volume and expansion of Nova Ortho & Spine. Despite strong adjusted EBITDA, net loss widened due to increased interest expense from higher-cost capital used to fund growth.
-
Q3 2025 saw revenue surge 125.6% year-over-year to $3.1M, with gross margin rising to 62.4%. Growth is driven by Nova Ortho and Spine’s scalable model, high collection rates, and a robust M&A strategy targeting expansion in underserved markets.
-
Q2 2025 saw 90% revenue growth and improved gross margins, driven by higher patient volume and surgical procedures. Despite a net loss due to high interest expense, adjusted EBITDA turned positive, and the company is focused on expanding capacity and pursuing M&A in a fragmented, high-demand market.